ArticleSynthetic and systems biotechnology2025
Combined metabolic and enzymatic engineering for
Article in Synthetic and systems biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A non-classical biosynthetic route enables tocopherol synthesis in bacteria.Nature metabolism · 2026Article
- Enhancing delta-tocotrienol production inSynthetic and systems biotechnology · 2026Article
- EngineeringSynthetic and systems biotechnology · 2026Article
- Modular reconstruction and multilevel regulation ofSynthetic and systems biotechnology · 2026Article
- Engineering Yarrowia Lipolytica for De Novo Biosynthesis of Abscisic Acid.Biotechnology journal · 2026Article
- A century of vitamin E research: The innovative journey from basic biology to synthetic bio-manufacturing.Journal of integrative plant biology · 2026Review
- Production of cycloastragenol in metabolically engineered yeast.Engineering microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
δ-Tocotrienol, an isomer of vitamin E with anti-inflammatory, neuroprotective and anti-coronary arteriosclerosis properties, is widely used in health care, medicine and other fields. Microbial synthesis of δ-tocotrienol offers significant advantages over plant extraction and chemical synthesis methods, including increased efficiency, cost-effectiveness and environmental sustainability. However, limited precursor availability and low catalytic efficiency of key enzymes remain major bottlenecks in the biosynthesis of δ-tocotrienol. In this study, we assembled the complete δ-tocotrienol biosynthetic pathway in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.